Last updated: 11/07/2018 12:11:26
Treatment Pathways in an Inception Lupus Cohort in Atlantic Canada
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Treatment Pathways in an Inception Lupus Cohort in Atlantic Canada
Trial description: The objective of this study is to describe current treatment patterns and sequence of therapeutic agents for lupus based on data from an inception cohort of systemic lupus erythematosus (SLE) patients in Atlantic Canada.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Primary
Timeframe: 3 years
Secondary outcomes:
Secondary
Timeframe: 3 years
Exploratory
Timeframe: 3 years
Interventions:
Other: N/A
Enrollment:
79
Observational study model:
Cohort
Primary completion date:
Not applicable
Time perspective:
Retrospective
Clinical publications:
John G Hanly, Amyn Sayani, Steve Doucette, Sandra Iczkovitz, Jorge Alfonso Ross Terres. Treatment pathways in an inception lupus cohort over the first three years. Lupus.2017;26(2):119-124.
Medical condition
Systemic Lupus Erythematosus
Product
belimumab
Collaborators
Not applicable
Study date(s)
July 2014 to July 2014
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
none
- Diagnosed with SLE based on ACR classification criteria
- Interval between diagnosis of SLE and enrollment in cohort of less than 12 months
- None
Inclusion and exclusion criteria
Inclusion criteria:
- Diagnosed with SLE based on ACR classification criteria
- Interval between diagnosis of SLE and enrollment in cohort of less than 12 months
- Minimum of 3 years of follow-up from time of enrollment in cohort
Exclusion criteria:
- None
Trial location(s)
No location data available.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2014-31-07
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website